SBIR/STTR Research Award
SBIR Phase I: Using patient specific DNA methylation to predict COVID-19 clinical prognosis
Award amount
$255,959Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- INHERENT BIOSCIENCES, INC.
- Proposal award date
- 2020-09-01
- Contract end date
- 2021-02-28
- UEI
- X9LJM6ADLJV7
- Solicitation number
- Not reported
- Topic code
- BM
Research abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the development of an onsite, clinical test to screen incoming patients potentially infected with COVID-19 and prioritize hospital resources and p
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility
- Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility
- Clinical epigenetic diagnostic for spermatogenic failure and future health risks
Research funding history
4 SBIR/STTR records share this UEI (2020–2024). Reported award amounts total $2,397,711. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation